Aurinia Pharmaceuticals Inc.
AUPH
$14.07
-$0.01-0.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.38% | 20.62% | 25.59% | 29.20% | 33.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.38% | 20.62% | 25.59% | 29.20% | 33.97% |
| Cost of Revenue | 28.27% | 35.69% | 1.65% | -2.76% | -4.78% |
| Gross Profit | 17.63% | 16.40% | 35.89% | 45.07% | 56.09% |
| SG&A Expenses | -40.83% | -40.79% | -33.97% | -24.89% | -11.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -110.95% | 379.99% | 1,299.07% | 622.06% | -37.35% |
| Total Operating Expenses | -25.07% | -22.85% | -22.49% | -19.42% | -14.81% |
| Operating Income | 828.68% | 526.03% | 234.13% | 167.65% | 114.59% |
| Income Before Tax | 1,432.72% | 495.41% | 229.91% | 167.75% | 109.61% |
| Income Tax Expenses | -10,303.13% | -25.22% | -17.90% | 129.74% | 207.80% |
| Earnings from Continuing Operations | 4,893.08% | 445.14% | 220.43% | 163.69% | 107.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4,893.08% | 445.14% | 220.43% | 163.69% | 107.37% |
| EBIT | 828.68% | 526.03% | 234.13% | 167.65% | 114.59% |
| EBITDA | 324.57% | 20,213.33% | 404.20% | 231.75% | 143.11% |
| EPS Basic | 5,205.15% | 466.82% | 224.51% | 164.82% | 107.47% |
| Normalized Basic EPS | 303.21% | 920.33% | 302.44% | 210.10% | 139.53% |
| EPS Diluted | 5,021.98% | 455.08% | 222.15% | 162.92% | 107.41% |
| Normalized Diluted EPS | 301.69% | 879.39% | 297.16% | 207.07% | 138.38% |
| Average Basic Shares Outstanding | -6.12% | -4.45% | -2.46% | -0.89% | 0.24% |
| Average Diluted Shares Outstanding | -4.57% | -2.13% | 0.03% | 1.41% | 1.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |